Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Myriad Genetics, Inc (NASDAQ: MYGN) closed at $4.13 in the last session, up 0.49% from day before closing price of $4.11. In other words, the price has increased by $0.49 from its previous closing price. On the day, 2.19 million shares were traded.
Ratios:
We take a closer look at MYGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.71 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.21.
On May 07, 2025, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.46 while its Price-to-Book (P/B) ratio in mrq is 0.54.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $3.81. The 50-Day Moving Average of the stock is -47.50%, while the 200-Day Moving Average is calculated to be -75.02%.
Shares Statistics:
A total of 92.20M shares are outstanding, with a floating share count of 87.74M. Insiders hold about 4.81% of the company’s shares, while institutions hold 102.40% stake in the company.
Earnings Estimates
The company has 12.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.01 and -$0.02 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.18, with 16.0 analysts recommending between $0.39 and $0.03.
Revenue Estimates
According to 13 analysts, the current quarter’s revenue is expected to be $202.3M. It ranges from a high estimate of $206.6M to a low estimate of $198.7M. As of the current estimate, Myriad Genetics, Inc’s year-ago sales were $211.5MFor the next quarter, 13 analysts are estimating revenue of $204.49M. There is a high estimate of $208.5M for the next quarter, whereas the lowest estimate is $201.6M.
A total of 13 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $818.2M, while the lowest revenue estimate was $806.2M, resulting in an average revenue estimate of $811.41M. In the same quarter a year ago, actual revenue was $837.6MBased on 16 analysts’ estimates, the company’s revenue will be $880.35M in the next fiscal year. The high estimate is $931.1M and the low estimate is $837.4M.
